The aims of this review are to recall the important results achieved with the use of HER-2 inhibitors in gastric and gastroesophageal junction cancers (as illustrated in Figure 1), and to discuss the updates on the role of HER-2 as prognostic and predictive factor in gastric and colorectal carcinomas. The gene discussed is ERBB2; the disease is colorectal carcinoma.